We started with the general expectation that (i) germline mutations should have a 50% allele fraction in both BM and PB samples; (ii) BM tumor mutations should have a greater allele fraction in the BM than the PB sample; and (iii) CH mutations should have a greater allele fraction in the PB than the BM sample. The gene discussed is C4B; the disease is neoplasm.